Hypermobility and Ehlers-Danlos Syndrome: The Complete Guide

Hypermobility means your joints move beyond the range that is typical for your age and sex. That is the simple version. The more useful version is that hypermobility sits on a spectrum, running from completely asymptomatic (the gymnast who never has a bad day) all the way to a connective tissue disorder that affects multiple body systems simultaneously.

Generalised joint hypermobility (GJH) is common. Depending on the population studied, estimates range widely, and it tends to decrease with age and is more prevalent in females and in people of South Asian and African descent. For many it is nothing more than a physical trait. The trouble starts when hypermobility comes with pain, instability, fatigue, autonomic symptoms, or other features that make daily life significantly harder [1,2].

When it comes to categorising where on that spectrum someone sits, the 2017 International Classification of the Ehlers-Danlos Syndromes is the current reference point [1]. It split the hypermobility world into two main categories that get confused constantly. The wider framing, hypermobility as a trait, as a disorder, or as one feature of a broader syndrome, is set out in detail by Morlino and Castori [17]. It is worth holding onto, because where someone sits on that spectrum changes what sensible management looks like.

Hypermobility Spectrum Disorder (HSD)

HSD is diagnosed in people who have symptomatic joint hypermobility, meaning it is causing real musculoskeletal problems, but who do not fully meet the clinical criteria for hEDS [2]. It is not a lesser condition, it is a separate diagnostic category. The symptoms, impact on quality of life, and comorbidities can be just as significant as in hEDS [19]. HSD replaced the old term “benign joint hypermobility syndrome,” and the word “benign” was rightly dropped. There is nothing benign about chronic pain and instability [18].

Hypermobile Ehlers-Danlos Syndrome (hEDS)

hEDS is the most common subtype of EDS. It is characterised by generalised joint hypermobility combined with a specific cluster of additional features: systemic connective tissue involvement, a positive family history, and the absence of conditions that would otherwise explain the symptoms [1]. Unlike the other 12 EDS subtypes, hEDS has no identified genetic marker. It cannot be confirmed or ruled out through a blood test, which creates significant diagnostic challenges [3].

Together, hEDS and HSD are far more common than most clinicians are taught. Population data suggests their combined prevalence is likely greater than 1 in 500 [4]. Some estimates put it considerably higher. For context, this makes the hEDS/HSD group one of the most common underdiagnosed connective tissue conditions in clinical practice.

It is also worth being clear about something that trips people up: you can have hypermobility without feeling or looking flexible. The internal laxity of connective tissue does not always translate to the splits on demand.

→ Read whether you can be hypermobile without looking flexible

Deconditioning worsens joint instability, amplifies pain sensitivity, and accelerates the downward spiral that many find themselves in. End-range loading, heavy ballistic movements, and anything that exploits the existing laxity rather than building stability around it tends to make things worse. The fundamentals of exercise for hypermobility lay out the framework that works.

Stretching: Less Than You Think

This is one of the most counter-intuitive aspects of managing hypermobility: the joints are already too mobile. Most people do not need more range. They need better control through the range they have got. Passive stretching, particularly into end range, often loads already compromised tissue and can increase instability over time. The truth about stretching in hypermobility explains the evidence and what to do instead. The same logic applies to the two practices most commonly recommended to hypermobile people: see our full reviews of what the evidence actually shows for Pilates in hypermobility and fibromyalgia and what the evidence shows for yoga in chronic pain and hypermobility.

Core Stability and Proprioceptive Training

Given that proprioceptive impairment is a key feature of hypermobility, exercises that specifically train joint position sense and neuromuscular control are particularly valuable. Graduated loading, stability work, and proprioceptive re-training tend to produce better outcomes than generic gym programmes. See our piece on core exercises for hypermobility for the practical version.

KT Tape and Supports

Taping can be a useful adjunct for joint stability, particularly during periods of flare or when specific joints are repeatedly subluxing. Taping, bracing, compression and the Body Braid now have a section of their own further down this guide. Jump to braces, supports, KT tape and compression.

→ Read the full exercise and rehabilitation guide for hypermobility

The 2017 international classification recognised 13 subtypes of EDS, each with its own clinical features, inheritance pattern, and in most cases, an identified genetic cause [1]. Here is a brief overview:

For most people reading this, hEDS is the relevant type. Vascular EDS is worth knowing about because it is the most serious and carries risks of arterial and organ rupture. If there is a family history of unexplained early cardiovascular events or bowel perforations, vascular EDS should be discussed with a genetics specialist.

The other 11 subtypes are genuinely rare. hEDS accounts for the vast majority of EDS cases seen in clinical practice, followed by classical EDS [13].

→ Read what the 2026 EDS classification update means for you

For most EDS subtypes, genetic testing can confirm or rule out a diagnosis. For hEDS, there is currently no genetic test available [1,3]. The 2017 international criteria are the current reference point.

The Beighton Score

The Beighton score is a 9-point scale used to measure generalised joint hypermobility. It tests five movements: forward spinal flexion (palms flat on floor with knees straight), plus four bilateral movements: hyperextension of the fifth finger beyond 90°, thumb to forearm, elbow hyperextension beyond 10°, and knee hyperextension beyond 10°. Each bilateral movement scores 1 point per side, the spinal test scores 1 point.

A Beighton score of 5 or more (in adults under 50) is used as one criterion for hEDS diagnosis. A score of 4 may also be sufficient in older adults. But it is worth understanding what the Beighton score is and is not. The score has real limitations, missing hypermobility in the hips, shoulders, ankles, and jaw. Plenty of people with significant systemic hypermobility score low, particularly if they have developed protective muscle tension or are older. The score was never designed as a standalone diagnostic tool, yet it is often used as one.

The 2017 hEDS Criteria

The 2017 diagnostic criteria for hEDS require three things to all be present:

• Criterion 1: Generalised joint hypermobility (meeting age/sex-specific Beighton thresholds, or a positive five-part questionnaire result)
• Criterion 2: Two or more of three feature groups: Feature A (systemic connective tissue manifestations including skin involvement, marfanoid features, stretch marks, hernia, pelvic floor dysfunction, dental crowding or palatal abnormalities); Feature B (positive family history, first-degree relative with confirmed hEDS); Feature C (musculoskeletal complications including at least three of musculoskeletal pain, recurrent joint dislocations, joint instability, etc.)
• Criterion 3: Exclusion of other heritable connective tissue disorders and conditions explaining the hypermobility

This is a more demanding criteria set than its predecessor, which means some people previously diagnosed with hEDS now fall into HSD. That is not a demotion. It is a more precise classification. The management approach is largely the same [18].

For a full walkthrough of the diagnostic process, this guide on how hypermobility and EDS are diagnosed covers it step by step. If other conditions could explain your symptoms, it is also worth reading about what can be mistaken for hypermobility.

→ Read the step-by-step guide on how hypermobility and EDS are diagnosed

The connective tissue that is behaving differently runs through virtually every structure in the body, which means symptoms can show up almost anywhere. The full symptom picture in hEDS and HSD is broader than most clinicians expect. Here are the main areas.

Chronic Pain

Chronic widespread pain is among the most common and most disabling features of hEDS and HSD [4,15]. It tends to be multifactorial. Joint instability causes microtrauma, but there is also evidence of altered central pain processing, reduced pain thresholds, and impaired conditioned pain modulation [15]. This is why straightforward pain-relief approaches often do not work well. The pain is not just coming from damaged joints. Neck pain in particular gets attributed to structural instability far more often than the evidence supports, which is covered in the guide to craniocervical instability in hypermobility and EDS. Understanding the mechanisms behind chronic pain in hypermobility is important before choosing how to address it.

For a comprehensive look at what the research says about different pain medications for this population, including NSAIDs, gabapentinoids, opioids, LDN, and local anaesthetic resistance, see our guide to pain medication for hypermobility and EDS.

Fatigue

Fatigue that does not respond to rest is one of the most reported symptoms and one of the hardest to explain to others. It is not laziness, it is physiological. The body’s constant effort to compensate for unstable joints, the disrupted sleep that often accompanies pain, the autonomic dysfunction, the deconditioning cycle. It all adds up.

Hypermobility does turn up more often in these groups than chance would predict. How much more often is genuinely unsettled, and the figure you see quoted depends almost entirely on who was studied and how they were assessed.

The range repeated most often, 30 to 57%, comes from the abstract of a single review that combined four separate conditions into one band [13]. That review’s own results section is more specific, giving 57% for POTS, 49% for ME/CFS, 30% for long COVID and 27% for fibromyalgia, against roughly 10 to 20% in the general population [13]. The shorthand has three problems. The fibromyalgia figure sits below the bottom of the range it is meant to fall inside, and neither endpoint belongs to the condition people usually attach it to [13]. The third problem is the comparator itself. That 10 to 20% is the same review’s estimate of how common hypermobility spectrum disorder is, which is a diagnosis requiring symptoms rather than a Beighton score, so it is not measuring the same quantity as the cohort figures set against it [13]. The review attributes the figure to a narrative review of joint hypermobility syndrome by Kumar and Lenert [13][29]. That is the same narrative review Bragée used for its own general population comparator, where the figure is given as roughly 3% instead [23][29]. One source, two papers, two general population figures that differ by more than sixfold [13][23][29]. We could not check how Kumar and Lenert arrived at either number, because the paper sits behind a paywall and only its abstract is readable [29]. Treat any comparison with the general population in this literature as the weakest part of the sentence.

ME/CFS. Reported prevalence runs from about 15% to 50% depending on the cohort and on where the hypermobility threshold is set [23][24]. The high end is Bragée and colleagues, who assessed 229 patients at a Swedish clinic taking referrals for severe ME/CFS [23]. That paper is worth reading carefully, because it reports three different figures for its own sample. Using the age and sex specific Beighton cutoffs of Singh it found generalised joint hypermobility in 115 participants, 50% [23]. Using a single fixed Beighton cutoff above 4 its results section reports 93 participants, 41% [23]. Its discussion then states that 49% had a Beighton score above 4, which contradicts its own results section for the same measure [23]. The 49% that circulates in review articles is that discussion sentence, not the abstract [13][23]. The low end is a registry analysis by Mudie and colleagues, in which 872 You and ME Registry participants completed a self-assessed Beighton score and 134 qualified as hypermobile, 15.4% [24]. That paper is not internally consistent either, because its abstract and discussion instead report 15.5% from a subset of 815 participants, so the same finding appears twice with different denominators [24]. Its authors attribute the distance from the Swedish figure to how hypermobility was classified and to the patient populations themselves, specifically a clinic specialty focus on orthostatic intolerance or on more severe disease [24]. Neither study recruited a healthy control group [23][24]. Every comparison Bragée draws runs against a separately published cohort rather than against people recruited alongside its own patients. For its optic nerve measurements that published cohort numbers 314 people, and for its craniocervical and disc findings it leans on two more, of 63 and 975 people [23]. For the hypermobility figure there is no reference cohort at all, only the narrative review discussed above [23][29]. The authors name the selection problem themselves, writing that “our patient cohort may differ from what is seen in other clinics as referral to our clinic requires that patients have severe symptoms indicating ME/CFS” [23]. That is the same mechanism Mudie’s team identified from the outside, conceded by the original authors, which carries more weight than any characterisation of their design we could offer [23][24].

Fibromyalgia. The 27% traces back to Acasuso-Díaz and Collantes-Estévez, who in 1998 found joint hyperlaxity in 18 of 66 women with fibromyalgia, 27.3%, against 8 of 70 women with other rheumatic diseases, 11.4% [25][26]. That study does have a comparator arm, which counts in its favour, although the comparison group had other rheumatic conditions rather than being healthy [25][26]. Two caveats sit alongside it. It applied the 1990 American College of Rheumatology fibromyalgia criteria, since revised, and it scored laxity on a Spanish modification rather than the Beighton scale [26]. The systematic review that later appraised it rated its quality poor, five out of twelve on the National Institutes of Health case-control checklist, placing it at high risk of bias [26]. That same review, by Alsiri and colleagues, covering eleven studies, found reported co-occurrence of generalised joint hypermobility and fibromyalgia spanning 8.0% to 64.2% [26]. The one study it rated good quality that also reported a prevalence figure gave 46.6%, well above the 27.3% that gets quoted [26]. A single figure of 27% cannot stand in for that spread [26].

Long COVID. Grach and colleagues surveyed patients at a United States long COVID clinic and found that 63 of 247 respondents, 27.0%, screened positive for generalised joint hypermobility, against 4 of 40 controls, 10.3% [27]. A real comparator arm is the most useful thing about that study, but it is 40 people, and only about a third of the patients invited returned a survey [27]. The same paper rounds its own 27.0% up to around 30% in its discussion [27].

One number that is not a prevalence. A separate UK study by Eccles and colleagues held recovery data on 2,854 people from the COVID Symptom Study Biobank who reported a COVID infection [28]. Those with generalised joint hypermobility were more likely to report not having recovered, at an odds ratio of 1.43 (95% CI 1.20 to 1.70) unadjusted, and 1.33 (95% CI 1.10 to 1.60) after adjustment for age, sex, ethnic group, education, deprivation and vaccination [28]. That is the origin of the phrase 30% more likely, and it is a ratio between two groups rather than a proportion of patients [28]. In absolute terms, 269 of the 914 participants who reported no recovery had hypermobility, 29.4%, against 439 of 1,940 who had recovered, 22.6% [28]. Both the hypermobility screen and the recovery outcome were self-reported [28]. This distinction matters, because two different 30% figures circulate about hypermobility and long COVID, one a prevalence and one a ratio, and at least one published paper places them side by side in a single sentence as though they agree [27].

The association itself looks real and it shows up across every cohort studied. Its size is not settled. The spread, 8% to 64% in fibromyalgia and 15% to 50% in ME/CFS, tracks who was recruited and how they were measured far more closely than it tracks anything about the conditions [24][26]. Every figure above is cross-sectional co-occurrence. None of them establishes a shared mechanism.

Gastrointestinal Issues

GI symptoms are extraordinarily common. Research comparing hEDS/HSD patients to controls found abdominal pain in 69% (versus 27% of controls), constipation in 73% (versus 16%), and diarrhoea in 47% (versus 9%) [10]. The causes are multiple: connective tissue laxity in the gut wall itself, autonomic dysfunction affecting motility, mast cell involvement, and the side effects of medications. Delayed gastric emptying (gastroparesis) is increasingly being recognised as a feature [21]. This matters more now that GLP-1 receptor agonists like Ozempic, Wegovy and Mounjaro are widely prescribed, since those drugs slow the gut further as part of how they work, which is something anyone with EDS considering Ozempic needs to factor into the conversation with their doctor. We have written about why constipation in hypermobility is not a fibre problem and the evidence-based approach to it, including the rectal hyposensitivity finding that explains why standard advice so often fails.

POTS and Dizziness

Postural orthostatic tachycardia syndrome, or POTS, is a form of dysautonomia in which the heart rate increases by more than 30 beats per minute on standing (or exceeds 120 bpm), often accompanied by lightheadedness, brain fog, nausea, and near-fainting. It is closely linked to hypermobility. 31% of POTS patients met full criteria for hEDS in one study using the 2017 criteria, with a further 24% having GJH without meeting full hEDS criteria [5]. The likely mechanism is that lax connective tissue allows excessive venous pooling in the legs on standing, reducing cardiac return and triggering compensatory tachycardia [21].

Brain Fog

Cognitive difficulties including concentration problems, word-finding difficulties, and difficulty processing information are widely reported. The causes are not fully understood but are thought to involve cerebral blood flow reductions secondary to POTS, disrupted sleep, the neurological effects of chronic pain, and possibly direct neurological involvement. A detailed look at brain fog in EDS and POTS covers this in full.

Anxiety

Those with hypermobility have a significantly elevated risk of anxiety disorders. The relationship is not simply psychological. It is physiological. Joint hypermobility syndrome at age 18 was associated with an adjusted odds ratio of 3.14 for anxiety disorder in a large cohort study, with the effect mediated by autonomic factors including elevated resting heart rate [9]. The body’s threat-detection systems are genuinely more active. Why anxiety is wired into hypermobility at a physiological level is one of the most important things to understand.

Sleep Problems

Poor sleep is near-universal in hEDS and HSD. Pain makes it hard to find a comfortable position, autonomic dysregulation can cause night-time heart rate spikes, and anxiety interferes with both falling and staying asleep. Restless legs syndrome is another common night-time driver in hypermobility and EDS. The full picture of sleep in hypermobility covers both the causes and practical approaches.

Skin and Wound Healing

Skin features in hEDS can be subtle, but many people notice unusually soft or velvety skin, easy bruising, slow wound healing, or pronounced stretch marks. The collagen dysfunction that underpins EDS affects skin structure. Interestingly, the same collagen differences may mean those with hypermobility often appear younger than their age.

→ Read the full hypermobility symptom guide

Collagen and the Extracellular Matrix

Connective tissue is the structural framework of the body. It holds joints together, supports organ walls, forms the scaffolding within skin, lines blood vessels, and more. Its primary structural protein is collagen, and the rest of the extracellular matrix (ECM): fibronectin, elastin, tenascin, proteoglycans. All of it works with collagen to give tissue its mechanical properties [3,14].

In the genetically confirmed EDS subtypes, there are known mutations affecting collagen biosynthesis, cross-linking, or assembly. The 2017 classification identified 13 subtypes with 19 causal genes [3]. In hEDS, no causative gene has been found, but research consistently shows ECM disorganisation in patient tissue. One 2024 study found a distinctive fragmentation pattern in fibronectin, type I collagen, and tenascin in plasma from hEDS and HSD patients, supporting the hypothesis that both conditions share a common ECM disruption even without an identified genetic cause [16].

Questions remain about whether those with hypermobility have less collagen overall, or whether the collagen they have is structurally different. The research on collagen in hypermobility goes into this in detail.

Proprioception: The Body’s Sixth Sense

Proprioception is the body’s ability to sense its own position in space. It depends on mechanoreceptors, sensory neurons embedded in joint capsules, tendons, and muscles, feeding signals back to the brain. In symptomatic hypermobility, this system is compromised. The loose, compliant connective tissue surrounding joints reduces the precision of position sensing, contributing to poor coordination, a tendency to misjudge joint position, and elevated injury risk.

This proprioceptive impairment is not trivial. It partly explains why chronic pain develops in hypermobility. The brain receives inconsistent and imprecise sensory signals from joints that are moving in uncontrolled ways, and the nervous system escalates its alarm responses accordingly. The result is a pain system that has been sensitised over years of sub-optimal mechanical feedback.

The Autonomic Nervous System

The autonomic nervous system controls unconscious body functions: heart rate, blood pressure, digestion, sweating, breathing. In hEDS and HSD, autonomic dysfunction is common. The mechanisms are thought to include the mechanical effects of lax connective tissue on blood vessels (reducing venous return), altered baroreceptor function, and possible neurological involvement [8,21].

This is why POTS, GI dysmotility, temperature dysregulation, and anxiety can all appear in the same person. They share an autonomic root. It also connects to how the brain and body interact in chronic illness.

→ Read more on what the research says about collagen in hypermobility

Multimorbidity is the rule here rather than the exception. A 2024 analysis of people with hEDS identified distinct phenotypic clusters, meaning the conditions that travel together tend to do so in recognisable patterns rather than at random [20]. That is clinically useful, because it means one diagnosis should prompt sensible questions about the others rather than being treated in isolation.

POTS (Postural Orthostatic Tachycardia Syndrome)

POTS and hypermobility are closely linked. In one study, 31% of POTS patients met criteria for hEDS, and a further 24% had GJH without the full diagnosis [5]. The connection runs in both directions. Exercise management for POTS requires a specific approach, and the evidence on salt in POTS management is more complex than many guides suggest.

Mast Cell Activation Syndrome (MCAS)

MCAS involves inappropriate mast cell degranulation, triggering allergic-type responses (flushing, hives, GI symptoms, anaphylactic reactions) in the absence of a clearly identifiable allergen. The association with hEDS is clinically well-recognised [11]. The biological mechanism is not fully established, but the close co-occurrence of hEDS, POTS, and MCAS (sometimes called the “triad”) is widely reported in clinical settings. What you need to know about MCAS covers diagnosis and management.

Autism and ADHD

The neurodevelopmental connections to hypermobility are real and increasingly well-documented. In a nationwide Swedish cohort study, EDS was associated with an autism risk ratio of 7.4 and an ADHD risk ratio of 5.6 compared to the general population [6]. A retrospective study of children with HSD/hEDS found 16% had a confirmed ADHD diagnosis, with a further 7% under investigation [7]. A separate study found that neurodivergent adults had a GJH prevalence of roughly 51% versus approximately 20% in the general population, and joint hypermobility mediated the link between neurodivergence and both dysautonomia and pain [8].

This is not well understood yet, but the overlap appears to involve shared genetic pathways, proprioceptive processing differences, and autonomic dysfunction [6,8]. The research on hypermobility and autism looks at this in more detail, as does what neuroscience tells us about brain differences in ASD and ADHD.

Depression and Anxiety

Beyond the direct physiological mechanisms, those with hypermobility face elevated rates of depression. EDS is associated with a 3.4-fold increased risk of depression and a 2.1-fold increased risk of suicide attempt in population-level data [6]. Joint hypermobility syndrome at age 18 was associated with a 3.53-fold increase in depressive disorder [9]. This is not just a reaction to living with a difficult condition. It reflects genuine neurobiological overlap, including autonomic dysregulation, altered interoception, and the psychological effects of years of unvalidated symptoms [9].

Hormonal and Gynaecological Conditions

Rates of gynaecological symptoms are substantially higher in hEDS, and hormonal fluctuation is one of the more consistently reported flare triggers. There is enough here that it now has its own section further down, covering periods, endometriosis, PCOS, pregnancy, menopause and the pelvic floor. Jump to hormones, reproductive health and the pelvic floor.

Scoliosis and Structural Issues

Spinal curvature is more common in hypermobility, partly because joint laxity affects the support structures around the spine. The relationship between scoliosis and hypermobility covers what to look for and how it affects management.

Weight Changes

Both unexplained weight gain and unintentional weight loss are reported in hEDS. GI dysmotility can affect absorption and appetite, medications have metabolic effects, and reduced activity due to pain and fatigue affects energy balance. How EDS affects body weight looks at the evidence. There is also a related question around whether losing weight increases subluxation risk in hypermobility.

→ Read more on the link between hypermobility and autism

Postural orthostatic tachycardia syndrome is a form of dysautonomia defined by a sustained heart rate rise on standing without a matching drop in blood pressure. In one study using the 2017 criteria, 31% of POTS patients met full criteria for hEDS, with a further 24% having generalised joint hypermobility without meeting them [5]. The mechanism most often proposed is mechanical: lax connective tissue permits excessive venous pooling in the legs on standing, cardiac return falls, and the heart compensates by beating faster [21].

The overlap is broad enough that we maintain a separate hub for it. What follows is the hypermobility-facing summary.

The Subtypes Matter

POTS is a description of a haemodynamic pattern, not a single disease, and treating it as one is where a lot of management goes wrong. The hyperadrenergic presentation in particular behaves differently and often responds differently, which is covered in what the evidence actually says about hyperadrenergic POTS. The clustering of POTS with hEDS and mast cell activation is common enough in clinic to have earned a nickname, and we have gone through what is solid and what is assumed in POTS, EDS and MCAS, understanding the trifecta.

What the 2026 Guidelines Changed

The guidance was updated in 2026, and it moved in some genuinely useful directions while leaving other things unaddressed. Our read of what changed in the 2026 POTS guidelines, and what they still got wrong covers both.

Coat Hanger Pain and Other Signs People Miss

Pain across the neck, shoulders and upper back that comes on with upright posture and eases when lying down is a recognised orthostatic symptom rather than a musculoskeletal one, and it gets treated as a shoulder problem constantly. What coat hanger pain actually is explains the pattern. Low blood pressure and its overlap with fatigue is covered in fibromyalgia and low blood pressure, and the cognitive side is in brain fog in EDS, POTS and long COVID.

Sleep

Autonomic dysfunction does not politely stop at bedtime. Night-time heart rate spikes, temperature dysregulation and unrefreshing sleep are all common. POTS and sleep, why rest does not come easily goes through what actually helps.

What Actually Helps

The non-drug foundations are exercise, fluid and salt, and compression, and the order in which you introduce them matters. POTS and exercise, the first step everyone misses is the place to start, because starting upright is the most common reason people fail. The evidence on salt in POTS is more nuanced than the standard advice suggests, and what the evidence says about compression garments covers where the pressure needs to be to do anything useful. Medication is covered in its own section below.

→ Read the full POTS and Dysautonomia guide

Headaches and Migraines

Headache is one of the most commonly reported symptoms in hypermobility and one of the least well explained to patients. There are several distinct mechanisms in play, they respond to different things, and telling them apart is most of the work. Headaches and migraines in hypermobility and EDS goes through the types, including the orthostatic and cervicogenic patterns that get repeatedly misfiled as migraine.

The Neck and Craniocervical Instability

This is an area where the online conversation has run considerably ahead of the evidence, and the consequences of getting it wrong are surgical. Neck pain in hypermobility is common. Craniocervical instability, in the strict radiological sense, is not. What the evidence actually says about craniocervical instability is worth reading before any consultation on the subject, in either direction.

The Jaw

The temporomandibular joint is a joint like any other, and it is not covered by the Beighton score, which is one reason jaw involvement gets overlooked in people who otherwise score low. Clicking, locking, pain on chewing and headaches referred from the jaw are all common. TMJD exercises for hypermobile jaw pain covers the practical side.

Throat, Swallowing and Voice

Globus sensation, a hoarse or tiring voice, swallowing difficulty and reflux are reported far more often in hEDS than most clinicians expect, and they have plausible mechanical and autonomic explanations rather than being anxiety by default. Why hEDS affects swallowing, voice and reflux covers what is going on and what to ask for.

→ Read the full guide to headaches and migraines in hypermobility and EDS

Gynaecological symptoms are markedly more common in hEDS. In a cohort of 386 women with the hypermobility type, 76% reported menorrhagia, 72% dysmenorrhoea, 43% dyspareunia, and 28% had experienced spontaneous abortion [12]. Those are self-reported figures from a single clinic cohort rather than population prevalence, so treat them as an indication of how common this is in people who reach specialist care, not as your personal odds.

The Cycle and Symptom Fluctuation

Many people report that joint instability, pain and fatigue shift predictably across the menstrual cycle. The mechanism usually proposed involves the effects of oestrogen and relaxin on connective tissue laxity. It is a reasonable hypothesis with limited direct evidence in hEDS specifically, and anyone telling you it is settled science is overselling it. What is not in doubt is that the pattern is reported often enough to be worth tracking, because a predictable flare is a manageable one.

Endometriosis

This one needs careful handling. hEDS symptoms can closely mimic endometriosis, the two can genuinely co-occur, and confusing them has led to surgery that was never going to help [12]. The link between EDS and endometriosis covers the current thinking.

PCOS, or PMOS

The condition long known as polycystic ovary syndrome is in the process of being renamed, and the change is more than cosmetic, because the old name described a finding that not everyone with the condition actually has. What the new name means for women with hypermobility goes through it.

Pregnancy and Postpartum

Pregnancy with EDS or hypermobility raises specific considerations around connective tissue changes, anaesthesia, labour and postpartum recovery, and local anaesthetic resistance is a conversation worth having well before you need it. Our guide to EDS, hypermobility and pregnancy covers preconception planning through to breastfeeding, including the 2024 expert guidelines.

Menopause and Perimenopause

Falling oestrogen affects connective tissue, bone, sleep and thermoregulation at the same time, which makes perimenopause a period where several hypermobility symptoms can worsen at once and get attributed to the wrong thing. How hormonal changes affect a hypermobile body covers what to expect and what to ask about.

The Pelvic Floor

The pelvic floor is connective tissue and muscle doing a demanding job, and it is affected in hypermobility more often than it is asked about. Incontinence, prolapse, pain with sex and incomplete emptying are all common and all treatable, and the default advice to do more pelvic floor squeezes is not always the right answer. The full pelvic floor guide for hypermobility and EDS covers assessment and management, and pelvic floor pain and sex deals with the part that rarely gets raised in clinic.

→ Read the comprehensive pelvic floor guide for hypermobility and EDS

The fatigue in hypermobility is not one thing. Unstable joints demand constant low-level muscular compensation, sleep is frequently disrupted, autonomic dysfunction adds its own load, and deconditioning compounds all of it. Treating it as a single problem with a single fix is why so many management plans fail.

Breathlessness and CO2 Tolerance

Breathlessness that does not match your exertion level, air hunger, and the feeling of not being able to get a satisfying breath are common and rarely investigated properly. Breathing pattern and carbon dioxide tolerance are a plausible and under-discussed part of the picture. The missing link between breathlessness, fatigue and chronic pain explains the mechanism and what can be trained.

The ME/CFS Overlap

There is substantial overlap between hypermobility, ME/CFS and fibromyalgia, and it is more than diagnostic untidiness. Shared features include autonomic dysfunction, disrupted sleep, and altered central pain processing [13,15]. The practical consequence is that if post-exertional symptom worsening is part of your picture, a graded exercise plan built for a purely deconditioned body is the wrong plan, and it can make things worse.

Pacing, Not Pushing

Pacing is the single most useful skill in this section and the most frequently misunderstood. It is not doing less. It is distributing load so the crash never arrives to collect. The complete evidence-based pacing guide is the place to start, and pacing intimacy with POTS, fatigue and ME/CFS applies it to the part nobody plans for.

Fear of Movement

When exertion has repeatedly cost you days, avoiding it is a rational response, not a psychological failing. It also becomes its own problem over time. Fear of movement in hypermobility and EDS covers why it happens and what actually helps, without any of the just-push-through nonsense.

→ Read the complete evidence-based guide to pacing

Start With the Extrapolation Problem

Read this bit before the rest, because it changes how you should read everything below. There is very little drug trial evidence in hEDS and HSD specifically. Most of what gets prescribed has been tested in fibromyalgia, neuropathic pain or general chronic pain populations and then applied to hypermobility on the assumption that the mechanisms are close enough. Sometimes that assumption is reasonable. Sometimes it is not, and nobody has checked, which is a gap the pain research in EDS has itself acknowledged [15].

That is not an argument against taking medication. It is an argument for honesty about what the evidence base actually is, and for treating any confident claim about a drug being effective “for EDS” with the suspicion it has earned. Everything below points to what the research shows in the populations it was genuinely tested in, with the caveat attached rather than quietly dropped.

None of this is medical advice, and nothing here should be started, stopped or changed on the strength of a web page. It is here so you can have a better conversation with the person who prescribes.

Pain Medication: The Overview

Our fullest treatment of this is pain medication for hypermobility and EDS, which goes through NSAIDs, opioids, gabapentinoids, low dose naltrexone and local anaesthetic resistance in one place, including where the evidence is genuinely thin.

Antidepressants Used for Pain

Duloxetine and amitriptyline are both prescribed for chronic pain at doses and for reasons that have nothing to do with treating depression, which is worth knowing before the conversation, because being handed an antidepressant for a pain problem lands badly if nobody explains why. What the evidence actually says about duloxetine and what we know about amitriptyline go through the trial data, the doses and the side effect profiles.

Gabapentinoids

Gabapentin is widely prescribed for chronic pain. Our review of what the evidence actually says about gabapentin in fibromyalgia goes through the trials, the quality of them, and what the side effect profile means in practice.

Low Dose Naltrexone

LDN attracts a lot of enthusiasm online and a more measured picture in the literature. Low dose naltrexone for fibromyalgia covers what has actually been tested and how large the trials were.

Tonmya

A newer entrant, and one where the trial data, the critics and the patient reports do not all say the same thing. Tonmya for fibromyalgia lays out all three.

POTS Medication

Drug treatment for POTS is aimed at the haemodynamics rather than at hypermobility, and the choice depends heavily on which pattern you have. Beta blockers for POTS and ivabradine for POTS cover what the evidence supports for each, and the hyperadrenergic presentation is where getting the subtype right matters most.

Medication, Weight and the Gut

Several drugs used in this population affect appetite, weight and gut motility, which matters more than usual when GI dysmotility is already part of the picture. Fibromyalgia, weight gain and medication covers the mechanism. GLP-1 agonists deserve their own mention, because slowing gastric emptying is part of how they work, and what the evidence says about Ozempic, EDS and hypermobility covers what to factor in before starting one.

Local Anaesthetic Resistance

Reduced or short-lived response to local anaesthetic is reported often enough in EDS that it is worth raising before dental work, minor procedures and childbirth rather than discovering it during them. The evidence is largely observational and the mechanism is not established, so it belongs in the “flag it in advance” category rather than the “settled fact” one. It is covered in our pain medication guide.

→ Read the full guide to pain medication for hypermobility and EDS

Diet

When it comes to eating with hEDS or HSD, the main goals are reducing systemic inflammation, supporting connective tissue health, and managing any GI comorbidities that affect absorption. An anti-inflammatory diet is the most commonly cited approach, and the full evidence-based guide to diet in hypermobility covers what that actually means in practice, beyond generic advice. Mast cell considerations may also affect food choices in those with MCAS comorbidity, and FODMAP management is sometimes relevant for those with significant GI symptoms.

Creatine

Creatine is one of the most robustly studied supplements in exercise science and has a plausible case for benefit in hypermobility. It supports phosphocreatine resynthesis in muscles, improves high-intensity exercise capacity, and may support connective tissue health through its effects on muscle function and reduced fatigue during training. The evidence for creatine in hypermobility and EDS looks specifically at what the research supports and how to use it effectively.

Vitamin C, magnesium, and omega-3 fatty acids are also commonly discussed in this context, though the evidence base is thinner. The key is matching any supplementation strategy to your individual symptom profile.

→ Read the full evidence-based guide to diet in hypermobility

The honest summary is that most external supports have limited high-quality evidence in hypermobility specifically, and the trials that do exist are typically small, short and unblinded, which matters enormously for something you can feel on your body. Blinding is essentially impossible when the intervention is a garment, so expectation effects are baked into the results. None of that means people are imagining the benefit. It means the size of the benefit is harder to pin down than the marketing suggests.

Taping

Taping can be a useful short-term adjunct during flares or when a specific joint is repeatedly subluxing. The most plausible mechanism is sensory rather than mechanical, since elastic tape does not meaningfully restrain a joint, but it does give the nervous system something extra to work with. How to use KT tape in hypermobility and EDS covers application and what the evidence supports.

Braces and Splints

Rigid and semi-rigid braces, and finger ring splints, have a genuine place, particularly for joints that sublux during specific tasks. The concern regularly raised is that long-term passive support substitutes for active control and lets the surrounding musculature do less. Direct evidence for that in hypermobility is limited, so treat it as a reasonable caution rather than a proven harm. The practical position we take: use support to enable activity you could not otherwise do, not to replace the work of building control.

Compression

Compression garments do two different jobs that often get conflated. For POTS and orthostatic symptoms the target is venous pooling, and the evidence points to abdominal and full-leg coverage mattering more than the knee-high socks most people are handed. For joints and proprioception, the rationale is sensory feedback. What the evidence actually says about compression garments separates the two.

The Body Braid

The Body Braid comes up constantly, so Jonny and I bought one, wore it, and went through the research it is marketed on. The short version is that it is a genuinely well-made garment, and that the published evidence behind the specific claims is a good deal thinner than the marketing implies. Both of those things are true at once.

Our full Body Braid review. If you would rather watch than read, it covers the same ground.

The written version, including the study everyone points to and what it does and does not show, is in the Body Braid for hypermobility, what the evidence actually says.

Support During Intimacy

Rarely raised in clinic, regularly raised by clients. Bracing, taping and joint protection during intimacy covers the practical side without being coy about it.

→ Read our full Body Braid review

Sleep

Poor sleep is one of the biggest drivers of the pain-fatigue cycle in hypermobility. Pain disrupts sleep, poor sleep lowers pain thresholds, which increases pain, and so on. Getting sleep architecture right, not just time in bed but sleep quality, matters significantly. Understanding sleep in hypermobility covers the causes and practical strategies in detail, including the roles of positioning, autonomic function, and the anxiety overlap.

Pacing

Pacing is the practice of managing activity levels to avoid boom-and-bust cycles, specifically periods of doing too much followed by crashes that can last days or weeks. It is not about doing less; it is about distributing energy and load more evenly. The evidence-based pacing guide for EDS and chronic pain is the place to start.

Flare Management

Flares are periods of increased symptoms: more pain, more fatigue, more instability. They can be triggered by physical overexertion, illness, stress, hormonal fluctuation, or sometimes nothing identifiable at all. Having a pre-planned response matters more than reacting to each flare from scratch. Managing EDS flare-ups covers what tends to help and what does not.

→ Read the evidence-based pacing guide for EDS and chronic pain

Children Are Not Small Adults

Joint range is naturally greater in childhood and decreases with age, which means the same Beighton score means something different at eight than it does at forty-eight. Paediatric assessment uses a higher threshold for generalised joint hypermobility than the adult one for exactly this reason. A dedicated paediatric diagnostic framework was published in 2023 and is the reference point worth pointing a clinician towards if you are getting nowhere [22].

“Growing Pains”

Recurrent limb pain in children gets labelled growing pains and left there. Growth itself is not painful. The label is a description of when the pain happens, not an explanation of why, and in a hypermobile child it is worth asking whether joint instability and fatigue are doing the work instead. That is not a reason to medicalise every ache. It is a reason not to dismiss a pattern.

Exercise for Hypermobile Children

The principles are the same as in adults, control through range rather than more range, but the delivery has to be different, because a child will not do a rehab programme that is boring. Hypermobility exercises for children covers what works in practice.

Neurodivergence and School

The overlap between hypermobility and neurodevelopmental conditions is substantial, and in children it often shows up first as handwriting difficulty, fatigue, avoidance of PE, or being labelled lazy or clumsy [7,8]. The research on hypermobility and autism covers the association. It is also worth knowing that early adversity is associated with chronic pain outcomes, which is an argument for taking a child seriously the first time rather than the fifth.

This is an area we are actively expanding. If there is a paediatric topic you want covered, tell us.

→ Read the guide to hypermobility exercises for children

So in one sense, older people with hypermobility may become less hypermobile by the numbers. But that does not mean the condition becomes easier to live with. The cumulative effects of years of joint instability, repeated microtrauma, and chronic pain can mean that symptoms become more entrenched over time even as the Beighton score drops. Comorbidities may accumulate. The deconditioning cycle, if unchecked, can have significant long-term consequences.

The picture is also highly individual, and it is not uniformly negative. People who get good support early, who find the right exercise approach, and who manage the autonomic and sleep components often report meaningful improvements in quality of life. It is not a single direction. A detailed look at ageing with EDS goes through what the evidence actually shows.

→ Read a detailed look at ageing with EDS

Many patients have their symptoms attributed to anxiety, hypochondria, or deconditioning before a connective tissue problem is even considered.

Medical Trauma

Being dismissed, disbelieved, or mismanaged over years creates a particular kind of damage that sits alongside the physical condition itself. The impact of medical trauma in EDS addresses this directly, covering both the experience and what recovery from it can look like. This matters because medical trauma can make people reluctant to engage with practitioners even when good support is available.

Finding Practitioners Who Understand

Not all physiotherapists, GPs, or specialists have working knowledge of hEDS and HSD. This is not entirely their fault. It is not well covered in standard medical training, but it does mean that navigating the healthcare system requires some self-advocacy. Key things to look for in a physiotherapist: understanding that end-range loading is problematic, focus on stability and neuromuscular control rather than passive stretching, awareness of the autonomic and fatigue components, and experience with hypermobility patients specifically.

The same principles apply to other professionals. A pain specialist who does not understand central sensitisation in connective tissue disorders, or a cardiologist who dismisses POTS as anxiety, is likely to cause more harm than good regardless of their individual expertise.

The Right Mental Model

Perhaps the most useful reframe for anyone newly diagnosed: this is a manageable condition, not a terminal one. The research on exercise response, pacing, and structured rehabilitation is genuinely encouraging. The challenge is finding the right level of support and building a management strategy that addresses the whole picture, not just one joint at a time.

→ Read about the impact of medical trauma in EDS